Hello. I'm Dr Maurie Markman from Cancer Treatment Centers of America in Philadelphia. I want to briefly highlight a new development in the management of ovarian cancer which again emphasizes the importance of PARP inhibitors in this malignancy.
The US Food and Drug Administration recently approved rucaparib as a maintenance strategy in patients with ovarian cancer who responded to a second-line platinum-based chemotherapy regimen. This marks the third PARP inhibitor, joining olaparib and niraparib, approved for treatment in the maintenance setting.
The announcement reinforces what is well recognized now in the oncology community: that this class of agents is active both as a maintenance strategy and as a treatment strategy. A number of ongoing trials are looking to expand the indications. There is a lot of excitement about this approach, particularly about potential expansion of the patient population that might benefit. The indications do not specifically require a biomarker based upon the data for use of this agent in the maintenance setting.
The possibility of combining PARP inhibitors with antiangiogenic agents or checkpoint inhibitors for the management of ovarian cancer is clearly very exciting. Those trials are in progress and we all wait for results with great interest.
Again, I want to emphasize this very important development and the clear role that PARP inhibitors have in the management of patients with advanced ovarian cancer. Thank you for your attention.
Medscape Oncology © 2018 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Maurie Markman. 'Clear Role' for PARP Inhibitors in Advanced Ovarian Cancer - Medscape - Apr 17, 2018.